• Explore /
  • Poster
  • / NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer.

NOVA-II: Part 2 study to evaluate the safety and efficacy of OQL011 on VEGF inhibitor-associated hand-foot skin reaction in patients with cancer.

Abstract Video & Slides Poster

Authors

null

Anisha B Patel

MD Anderson Cancer Center, Houston, TX

Anisha B Patel , Milan J. Anadkat , Omkar Subhash Marathe , Mark L Webb , Robert Claude Tyler , Wenhui Zhang , Chengguang Wu , Juegang Ju , Hong Tang , Jie Luo , Mario E. Lacouture

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Clinical Trial Registration Number

NCT04088318

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS741)

DOI

10.1200/JCO.2023.41.6_suppl.TPS741

Abstract #

TPS741

Poster Bd #

M19

Abstract Disclosures

Similar Posters

First Author: Mario E. Lacouture

First Author: Mario E. Lacouture

First Author: Arthur Geraud

First Author: Jaekyung Cheon